Table 1.
Baseline demographic and clinical characteristics.
| AS group (n = 48) | SOX group (n = 49) | |
|---|---|---|
| Sex | ||
| Male | 25 (52.08%) | 29 (59.18%) |
| Female | 23 (47.92%) | 20 (40.82%) |
| Age, years | ||
| Median | 54.00 (49.00–63.50) | 56.00 (47.00–63.00) |
| <65 | 39 (81.25%) | 39 (79.59%) |
| ⩾65 | 9 (18.75%) | 10 (20.41%) |
| ECOG PS | ||
| 0 | 24 (50.00%) | 22 (44.90%) |
| 1 | 24 (50.00%) | 27 (55.10%) |
| Primary tumor location | ||
| Proximal | 10 (20.83%) | 8 (16.33%) |
| Body | 17 (35.42%) | 17 (34.69%) |
| Distal | 13 (27.08%) | 20 (40.82%) |
| Multiple/diffuse | 6 (12.50%) | 2 (4.08%) |
| Gastric remnant | 2 (4.17%) | 2 (4.08%) |
| Histology | ||
| Well differentiated | 1 (2.08%) | 0 |
| Moderately differentiated | 2 (4.17%) | 2 (4.08%) |
| Poorly differentiated/signet-ring cell | 35 (72.92%) | 35 (71.43%) |
| Unknown | 10 (20.83%) | 12 (24.49%) |
| Metastatic site | ||
| Liver | 12 (25.00%) | 13 (26.53%) |
| Lung | 2 (4.17%) | 2 (4.08%) |
| Peritoneum | 25 (52.08%) | 25 (51.02%) |
| Lymph node | 32 (66.67%) | 37 (75.51%) |
| Ovary | 9 (18.75%) | 8 (16.33%) |
| Others | 22 (45.83%) | 17 (34.69%) |
| Number of organs with metastases | ||
| <2 | 11 (22.92%) | 13 (26.53%) |
| ⩾2 | 37 (77.08%) | 36 (73.47%) |
| Massive ascites | ||
| Yes | 12 (25.00%) | 11 (22.45%) |
| No | 36 (75.00%) | 38 (77.55%) |
| Prior treatment | ||
| Curative gastrectomy | 8 (16.67%) | 4 (8.16%) |
| Palliative gastrectomy/metastasectomy | 13 (27.08%) | 14 (28.57%) |
| Prior adjuvant chemotherapy | 6 (12.50%) | 3 (6.12%) |
Data are median (IQR) or n (%).
AS, nab-paclitaxel plus S-1; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; SOX, oxaliplatin plus S-1.